Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 2:09 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,904 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: AstraZeneca Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body

NCT04187456
View directory record Official record
Conditions
Solid Tumors
Interventions
Savolitinib, Midazolam
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 4 Interventional

An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

NCT00352261
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Esomeprazole, Lansoprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
Phoenix, Arizona • Tucson, Arizona • North Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2009 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 2 Interventional Results available

Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer

NCT01499303
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
19
States / cities
Huntsville, Alabama • Denver, Colorado • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Nov 1, 2026, 2:09 AM EST
Completed No phase listed Observational

A Disease Registry of Patients With Mantle Cell Lymphoma

NCT03816683
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
32
States / cities
Montgomery, Alabama • Clovis, California • Boulder, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Nov 1, 2026, 2:09 AM EST
Terminated Phase 3 Interventional Results available

Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence

NCT00003645
View directory record Official record
Conditions
Prostate Cancer
Interventions
Flutamide, Leuprolide Acetate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 2 Interventional Results available

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

NCT04089553
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
AZD4635, Oleclumab, Durvalumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Nov 1, 2026, 2:09 AM EST
Terminated Phase 1 Interventional

A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

NCT04959266
View directory record Official record
Conditions
Advanced Solid Tumours
Interventions
Adavosertib, Itraconazole, Rifampicin, Omeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Portland, Oregon • Austin, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 1 Interventional Results available

A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT02367066
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AR-C165395XX, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 2 Interventional Results available

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT03693300
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Durvalumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Gainesville, Georgia • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 2 Interventional

Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes

NCT00064714
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
AC2993 (exenatide), daclizumab (immunosuppressive)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

NCT00658021
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo, Exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 3 Interventional Results available

A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia

NCT00463606
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
ABT-335 and rosuvastatin calcium, ABT-335, rosuvastatin calcium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
168
States / cities
Birmingham, Alabama • Huntsville, Alabama • Ozark, Alabama + 135 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 3 Interventional

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder

NCT00329264
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
58
States / cities
Springdale, Arizona • Little Rock, Arkansas • Encino, California + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

NCT02284893
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Dapagliflozin, Sitagliptin, Placebo matching with Saxagliptin, Placebo matching with Dapagliflozin, Placebo matching with Sitagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 1 Interventional

Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma

NCT00821080
View directory record Official record
Conditions
Glioblastoma
Interventions
Sirolimus, Vandetanib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 2 Interventional Results available

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

NCT03239340
View directory record Official record
Conditions
EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
Osimertinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Athens, Georgia • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers

NCT00726427
View directory record Official record
Conditions
Healthy
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2010 · Synced Nov 1, 2026, 2:09 AM EST
Terminated Phase 4 Interventional Results available

Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia

NCT04997161
View directory record Official record
Conditions
Hyperkalaemia
Interventions
Sodium Zirconium Cyclosilicate (SZC), Enhanced dietary advice, Standard dietary advice including K+ restriction.
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 4 Interventional Results available

Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients

NCT01823510
View directory record Official record
Conditions
Type-2 Diabetes Mellitus, Coronary Artery Disease
Interventions
Ticagrelor + Aspirin, Clopidogrel + Aspirin
Drug
Lead sponsor
Juan J Badimon
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 4 Interventional Results available

Adherence Study in COPD Patients

NCT02864342
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD
Interventions
Arm 1: BreatheMate device with application, Arm 2: BreatheMate device without application
Device
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Clearwater, Florida • Tampa, Florida • Marlton, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

NCT03959488
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MEDI8897, Palivizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 1 Year
Enrollment
925 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
30
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 1 Interventional Results available

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

NCT01597388
View directory record Official record
Conditions
Advanced Metastatic Breast Cancer
Interventions
AZD2014, Fulvestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
5
States / cities
Sarasota, Florida • Detroit, Michigan • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 3 Interventional Results available

CRESTOR Athero Imaging Head to Head IVUS Study

NCT00620542
View directory record Official record
Conditions
Coronary Atherosclerosis
Interventions
Rosuvastatin, Atorvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
2,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
97
States / cities
Huntsville, Alabama • Los Angeles, California • Mountain View, California + 94 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Nov 1, 2026, 2:09 AM EST
Completed Phase 4 Interventional

Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety

NCT00352469
View directory record Official record
Conditions
Alcoholism, Anxiety Disorders, Generalized Anxiety Disorder, Post-Traumatic Stress Disorder, Panic Disorder, Obsessive-Compulsive Disorder
Interventions
Seroquel XR
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 8, 2008 · Synced Nov 1, 2026, 2:09 AM EST